Johnson Luke, Ha Dat T, Hall Melissa B, Shoemaker Gregory, Bevins Paul A, Strickley John, Demehri Shadmehr, Redman Rebecca A, Joh Joongho
Department of Medicine, University of Louisville School of Medicine, KY 40202, USA.
Brown Cancer Center, University of Louisville School of Medicine, KY 40202, USA.
J Oncol. 2022 Sep 26;2022:3107990. doi: 10.1155/2022/3107990. eCollection 2022.
High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients' clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( = 48). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( = .004) with 100% specificity as a predictive test.
高危型人乳头瘤病毒（HPV）是头颈部癌（HNC）最常见的病因之一，其发病率呈上升趋势。HPV相关的HNC患者对治疗的临床反应差异很大，这使得降低治疗强度的临床试验具有挑战性。为了满足对能够区分患者预后的非侵入性生物标志物的需求，我们在48例HPV阳性HNC患者的系列血清标本中评估了针对E7癌蛋白水平的血清抗体。我们发现，在整个治疗过程中，针对E7的抗体增加与癌症复发增加或进展至死亡相关（P = 0.004），作为预测性检测，其特异性为100%。
